Article Figures & Data
Figures
- Figure 1
- Comparison of CBC parameters between patients with (A) chronic myeloid leukemia (CML) and (B) chronic lymphoid leukemia (CLL) and control groups. The total sample comprised 106 leukemic patients and 100 controls. Evaluated parameters include white blood cells (WBC), platelets (PLTs), hemoglobin (HB), red blood cells (RBCs), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), and mean platelet volume (MPV). *p<0.05, ***p<0.001
- Figure 2
- Comparison of CBC parameters between patients with (A) acute myeloid leukemia (AML), (B) B-cell acute lymphoid leukemia (B-ALL), and (C) T-cell acute lymphoid leukemia (T-ALL) and control groups. The total sample included 106 leukemic patients with 100 controls. Evaluated parameters include white blood cells (WBC), platelets (PLTs), hemoglobin (HB), red blood cells (RBCs), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), and mean platelet volume (MPV).*p<0.05, ***p<0.001.
- Figure 3
- Comparison of liver and kidney function tests between patients with (A) chronic myeloid leukemia (CML) and (B) chronic lymphoid leukemia (CLL) and control groups. The total sample includes 106 leukemic patients with 100 controls. Evaluated parameters include creatinine (CREA), total bilirubin (T. Bilirubin), direct bilirubin (D. Bilirubin), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total protein (T. Protein), and gamma-glutamyl transferase (GGT). *p<0.05, **p<0.01, ***p<0.001.
- Figure 4
- Comparison of liver and kidney function tests between patients with (A) acute myeloid leukemia (AML), (B) B-cell acute lymphoid leukemia (B-ALL), and (C) T-cell acute lymphoid leukemia (T-ALL) and control groups. The total sample includes 106 leukemic patients with 100 controls. Evaluated parameters include creatinine (CREA), total bilirubin (T. Bilirubin), direct bilirubin (D. Bilirubin), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total protein (T. Protein), and gamma-glutamyl transferase (GGT). *p<0.05, **p<0.01, ***p<0.001.
- Figure 5
- Comparison of coagulation profiles between patients with (A) chronic myeloid leukemia (CML), (B) acute myeloid leukemia (AML), (C) chronic lymphoid leukemia (CLL), (D) B-cell acute lymphoid leukemia(B-ALL), and (E) T-cell acute lymphoid leukemia (T-ALL) and control groups. The total sample includes 106 leukemic patients with 100 controls. Sig: ***p<0.001. PT: prothrombin time, APTT: activated partial thromboplastin, INR: international normalized ratio
Tables
- Table 1
- Distribution of leukemia cases by gender, type, and subtype among children aged 14 years or younger from 2012 to 2022.
Leukemia subtype Male Female Total ALL 7 (70) 3 (30) 10 (30.3) CML 5 (100) 0 (0) 5 (15.1) ALL-L2 4 (80) 1 (20) 5 (15.1) AML 0 (0) 2 (100) 2 (6) CLL 2 (100) 0 (0) 2 (6) ALL-L3 2 (100) 0 (0) 2 (6) AML-M4 0 (0) 2 (100) 2 (6) AML-M3 1 (100) 0 (0) 1 (3) ALL-L1 1 (100) 0 (0) 1 (3) AML-M2 1 (100) 0 (0) 1 (3) AML-M7 1 (100) 0 (0) 1 (3) AML-M1 1 (100) 0 (0) 1 (3) TOTAL 25 (75.7) 8 (24.2) 33 (100) Values are presented as numbers and percentages (%). ALL: acute lymphoid leukemia, CML: chronic myeloid leukemia, AML: acute myeloid leukemia
- Table 2
- Distribution of leukemia cases by gender, type, and subtype among adults aged 15 years or older from 2012 to 2022.
Leukemia subtype Male Female Total CML 43 (64.1) 24 (35.8) 67 (37.8) AML 23 (65.7) 12 (34.2) 35 (19.7) CLL 10 (43.4) 13 (56.5) 23 (12.9) B-ALL 9 (45.0) 11 (55.0) 20 (11.2) ALL 6 (66.6) 3 (33.3) 9 (5) ALL-L2 5 (62.5) 3 (37.5) 8 (4.5) AML-M3 2 (40) 3 (60) 5 (2.8) T-ALL 1 (33.3) 2 (66.7) 3 (1.6) ALL-L3 1 (50) 1 (50) 2 (1.2) AML-M4 0 1 (100) 1 (0.5) ALL-L1 1 (100) 0 1 (0.5) AML-M2 1 (100) 0 1 (0.5) AML-M7 1 (100) 0 1 (0.5) AML-M5 1 (100) 0 1 (0.5) TOTAL 104 (58.7) 73 (41.2) 177 (100) Values are presented as numbers and percentages (%). ALL: acute lymphoid leukemia, CML: chronic myeloid leukemia, AML: acute myeloid leukemia
